I R Reid

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi request reprint Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 346:653-61. 2002
  2. pmc Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis
    Mark J Bolland
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
    BMJ 342:d2040. 2011
  3. ncbi request reprint Government funding of health research in New Zealand
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    N Z Med J 127:25-30. 2014
  4. doi request reprint Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand Electronic address
    Lancet 383:146-55. 2014
  5. doi request reprint Osteoporosis treatment: focus on safety
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand Electronic address
    Eur J Intern Med 24:691-7. 2013
  6. pmc Cardiovascular effects of calcium supplements
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
    Nutrients 5:2522-9. 2013
  7. doi request reprint Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams
    I R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, 1142 Auckland, New Zealand
    J Clin Endocrinol Metab 98:557-63. 2013
  8. doi request reprint Role of vitamin D deficiency in cardiovascular disease
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Heart 98:609-14. 2012
  9. doi request reprint Pharmacotherapy of Paget's disease of bone
    Ian R Reid
    University of Auckland, Faculty of Medical and Health Sciences, Department of Medicine, Private Bag 92019, Auckland, New Zealand
    Expert Opin Pharmacother 13:637-46. 2012
  10. doi request reprint Epidemiology and pathogenesis of osteonecrosis of the jaw
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Nat Rev Rheumatol 8:90-6. 2012

Detail Information

Publications134 found, 100 shown here

  1. ncbi request reprint Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 346:653-61. 2002
    ..Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored...
  2. pmc Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis
    Mark J Bolland
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
    BMJ 342:d2040. 2011
    ....
  3. ncbi request reprint Government funding of health research in New Zealand
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    N Z Med J 127:25-30. 2014
    ..Urgent and sustained action is needed to correct these major disparities in government health research funding if the quality of academic and clinical staff in our public institutions is to be maintained. ..
  4. doi request reprint Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand Electronic address
    Lancet 383:146-55. 2014
    ..Bone mineral density can be used to detect biologically significant effects in much smaller cohorts. We investigated whether vitamin D supplementation affects bone mineral density...
  5. doi request reprint Osteoporosis treatment: focus on safety
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand Electronic address
    Eur J Intern Med 24:691-7. 2013
    ..Thus, they are not cost-effective, and a balanced diet is a safer way of obtaining one's calcium requirements. ..
  6. pmc Cardiovascular effects of calcium supplements
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand
    Nutrients 5:2522-9. 2013
    ..Thus, the non-skeletal risks of calcium supplements appear to outweigh any skeletal benefits, and are they appear to be unnecessary for the efficacy of other osteoporosis treatments. ..
  7. doi request reprint Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams
    I R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, 1142 Auckland, New Zealand
    J Clin Endocrinol Metab 98:557-63. 2013
    ..There is now evidence that the effects of a single dose of zoledronic acid on bone mineral density and bone turnover last for much more than a year. Whether this is associated with sustained fracture prevention is not known...
  8. doi request reprint Role of vitamin D deficiency in cardiovascular disease
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Heart 98:609-14. 2012
    ..Trials are underway to assess these possibilities further. At present, there is insufficient evidence to support vitamin D supplementation for improving cardiovascular outcomes...
  9. doi request reprint Pharmacotherapy of Paget's disease of bone
    Ian R Reid
    University of Auckland, Faculty of Medical and Health Sciences, Department of Medicine, Private Bag 92019, Auckland, New Zealand
    Expert Opin Pharmacother 13:637-46. 2012
    ..Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients...
  10. doi request reprint Epidemiology and pathogenesis of osteonecrosis of the jaw
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Nat Rev Rheumatol 8:90-6. 2012
    ..The management of established ONJ lesions is problematic: the greatest success seems to come from vigorous antimicrobial therapy with judicious use of surgical debridement...
  11. doi request reprint Does calcium supplementation increase cardiovascular risk?
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 73:689-95. 2010
    ....
  12. ncbi request reprint Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1020, New Zealand
    J Clin Endocrinol Metab 90:3824-9. 2005
    ..Epidemiological data suggest that high calcium intakes are associated with decreased body weight and blood pressure. However, there is little evidence from randomized trials that addresses these important issues...
  13. doi request reprint Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 25:2256-65. 2010
    ..Denosumab markedly reduces bone turnover and also reduces fracture numbers. Longer follow-up is necessary to determine how long such low turnover is safe...
  14. doi request reprint Characterization of and risk factors for the acute-phase response after zoledronic acid
    I R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, 1142 Auckland, New Zealand
    J Clin Endocrinol Metab 95:4380-7. 2010
    ..Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied...
  15. doi request reprint Fat and bone
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Arch Biochem Biophys 503:20-7. 2010
    ..In the clinic, the key issues are that obesity is protective against osteoporosis, but underweight is a major preventable risk factor for fractures...
  16. doi request reprint Bisphosphonates in Paget's disease
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
    Bone 49:89-94. 2011
    ....
  17. ncbi request reprint Direct actions of leptin on bone remodeling
    I R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 74:313-6. 2004
  18. ncbi request reprint Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, New Zealand
    Bone 35:224-30. 2004
    ..There is no clear evidence from this study that any of these newer markers are superior to total AP in assessing patients with this severity of Paget's disease...
  19. doi request reprint Cardiovascular effects of calcium supplementation
    I R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Osteoporos Int 22:1649-58. 2011
    ..Since food sources have not been associated with adverse cardiovascular effects, they may be preferable. Available evidence suggests that other osteoporosis treatments are still effective without calcium co-administration...
  20. ncbi request reprint Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 90:5212-6. 2005
    ..beta-blockers increase bone mass in mice, and some observational studies have suggested a beneficial effect of these drugs on bone in humans..
  21. doi request reprint Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Am J Clin Nutr 91:131-9. 2010
    ..Calcium supplementation has been suggested to have beneficial effects on serum lipids, blood pressure, and body weight, but these possibilities have not been rigorously assessed in men...
  22. ncbi request reprint Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 353:898-908. 2005
    ..Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs...
  23. ncbi request reprint Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Clin Endocrinol Metab 92:2446-52. 2007
    ..Treatment of osteoporosis with high-dose fluoride alone does not reduce fracture risk. We hypothesized that the antifracture efficacy of fluoride could be optimized by its use in low doses combined with an antiresorptive agent...
  24. ncbi request reprint Bisphosphonates
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Skeletal Radiol 36:711-4. 2007
  25. ncbi request reprint Relationships between fat and bone
    I R Reid
    University of Auckland, Auckland, New Zealand
    Osteoporos Int 19:595-606. 2008
    ..More immediately, the role of weight maintenance in the prevention of osteoporosis is an important public health message that needs to be more widely appreciated...
  26. doi request reprint Effect of calcium supplementation on hip fractures
    I R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019 Auckland, New Zealand
    Osteoporos Int 19:1119-23. 2008
    ..In addition, those at risk should be looking to other agents with a proven capacity to prevent hip fractures, such as bisphosphonates...
  27. ncbi request reprint Effects of beta-blockers on fracture risk
    I R Reid
    University of Auckland, Auckland, New Zealand
    J Musculoskelet Neuronal Interact 8:105-10. 2008
    ..Until there are definitive randomized, controlled trials of beta-blockers, which include fracture as an endpoint, it is unlikely that the current confusing situation will be resolved...
  28. doi request reprint Osteonecrosis of the jaw
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Skeletal Radiol 38:5-9. 2009
    ..Obvious abnormalities are apparent with a variety of radiologic modalities, and it is not clear that radiographs are inferior to other approaches. Most authors favor a conservative approach to surgical debridement of the lesions...
  29. doi request reprint Anti-resorptive therapies for osteoporosis
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Semin Cell Dev Biol 19:473-8. 2008
    ..Whether the newer agents can improve on this remains to be seen, though it is possible that anabolic agents which increase bone mass more substantially will be needed to achieve greater reductions in all fracture numbers...
  30. ncbi request reprint Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Bone 41:318-20. 2007
    ....
  31. doi request reprint Osteonecrosis of the jaw: who gets it, and why?
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Bone 44:4-10. 2009
    ..This is likely to result in the local release at high concentrations of bisphosphonates. Management focuses on prevention, treatment of infection and cessation of bisphosphonates. The role of surgery is unclear...
  32. ncbi request reprint Randomized controlled trial of calcium in healthy older women
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Am J Med 119:777-85. 2006
    ..However, these effects are small, it is unknown whether they are sustained with long-term use, they have not been shown with intention-to-treat analyses, and the evidence for fracture prevention with calcium monotherapy is inconsistent...
  33. doi request reprint Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Arch Intern Med 168:2276-82. 2008
    ..There is no consistent evidence, to our knowledge, that calcium supplementation affects bone mineral density (BMD) in men, despite male osteoporosis being a common clinical problem...
  34. ncbi request reprint Obesity and osteoporosis
    I R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Ann Endocrinol (Paris) 67:125-9. 2006
  35. ncbi request reprint Nutrition-related peptides and bone homeostasis
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:495-500. 2006
  36. ncbi request reprint A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women
    Ian R Reid
    Department of Medicine, University of Auckland, PB 92019, Auckland, New Zealand
    Arch Intern Med 164:871-9. 2004
    ..Although many studies have assessed the effects of estrogen and raloxifene hydrochloride on bone mineral density and serum lipid concentrations, there are few direct comparative data...
  37. doi request reprint Calcium supplementation: balancing the cardiovascular risks
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Maturitas 69:289-95. 2011
    ..Patients at high risk of fracture need to take interventions of proven anti-fracture efficacy. Available evidence suggests that this efficacy is not dependent on the co-administration of calcium supplements...
  38. ncbi request reprint Pharmacological management of osteoporosis in postmenopausal women: a comparative review
    I R Reid
    Department of Medicine, University of Auckland, New Zealand
    Drugs Aging 15:349-63. 1999
    ..There is a need for an effective bone anabolic factor but those which have been trialled to date have not proceeded because of significant adverse effects...
  39. ncbi request reprint Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women
    B J Orr-Walker
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Arch Intern Med 160:2161-6. 2000
    ..Longer-term data are required to further assess the efficacy of this treatment in chronic stable primary hyperparathyroidism...
  40. ncbi request reprint Preventing glucocorticoid-induced osteoporosis
    I R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Z Rheumatol 59:II/97-102. 2000
    ..It is incumbent on all physicians supervising long-term glucocorticoid therapy to ensure that a skeletal assessment is carried out and that osteoporosis prophylaxis is instituted, where appropriate...
  41. ncbi request reprint Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease
    I R Reid
    Department of Medicine, University of Auckland, New Zealand
    Lancet 357:509-12. 2001
    ..To assess whether statins have clinically significant effects on bone, we studied the frequency of fractures in a large randomised controlled trial of these agents...
  42. doi request reprint Evidence-based policy on dietary calcium and vitamin D
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 26:452-4. 2011
    ..However, we believe that the central role of sunlight exposure in determining vitamin D status needs to be explicitly reflected in public policy in this area...
  43. ncbi request reprint Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Expert Opin Drug Saf 1:93-107. 2002
    ..While none of these options is suitable for everyone, the range of available therapies does mean that most patients can find an intervention that is effective and acceptable...
  44. ncbi request reprint A new receptor to turn on bone growth
    Ian R Reid
    Department of Medicine, University of Auckland
    N Z Med J 115:169-70. 2002
  45. ncbi request reprint Relationships among body mass, its components, and bone
    I R Reid
    Department of Medicine, University of Auckland, New Zealand
    Bone 31:547-55. 2002
    ..More immediately, the role of weight maintenance in the prevention of osteoporosis is an important public health message that needs to be more widely appreciated...
  46. doi request reprint Bisphosphonate therapy for secondary osteoporosis: adult perspective
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Horm Res Paediatr 76:28-32. 2011
    ..Upper gastrointestinal tract intolerance with oral agents and a flu-like syndrome with intravenous bisphosphonates are the principal adverse effects associated with their use...
  47. ncbi request reprint Bisphosphonates: new indications and methods of administration
    Ian R Reid
    Department of Medicine, University of Auckland, New Zealand
    Curr Opin Rheumatol 15:458-63. 2003
    ..The role of bisphosphonates in osteogenesis imperfecta was further confirmed, and novel roles in ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy were suggested...
  48. doi request reprint A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 26:2261-70. 2011
    ..01). Bone markers at 6 months were predictive of response duration. These data demonstrate an unprecedented duration of remission of Paget disease following treatment with zoledronic acid, accompanied by an improved quality of life...
  49. ncbi request reprint beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 20:613-8. 2005
    ..We studied the association of beta-blocker use with BMD and fractures in the Study of Osteoporotic Fractures. beta-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent...
  50. doi request reprint Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies
    Ian R Reid
    Faculty of Medical and Health Sciences, University of Auckland Auckland, New Zealand
    Skeletal Radiol 40:1191-6. 2011
    ....
  51. ncbi request reprint Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Drugs Aging 21:7-17. 2004
    ..Therefore, caution is appropriate in incorporating these findings into clinical practice, but the balance of evidence suggests that calcium is a cost-effective adjunct to the dietary management of hyperlipidaemia...
  52. ncbi request reprint Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo
    J Cornish
    Dept of Medicine, Univ of Auckland, Private Bag 92019, Auckland, NZ, USA
    Am J Physiol Endocrinol Metab 292:E117-22. 2007
    ..These data demonstrate that preptin, which is cosecreted from the pancreatic beta-cell with amylin and insulin, is anabolic to bone and may contribute to the preservation of bone mass observed in hyperinsulinemic states such as obesity...
  53. ncbi request reprint Systemic administration of a novel octapeptide, amylin-(1---8), increases bone volume in male mice
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol Endocrinol Metab 279:E730-5. 2000
    ..Amylin-(1---8) thus has significant anabolic effects in vivo, suggesting that this peptide or analogs of it should be further evaluated as potential therapies for osteoporosis...
  54. ncbi request reprint Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol 277:E779-83. 1999
    ..Such peptides should be converted to a hydrochloride or biologically equivalent salt before assessment of their biological effects is undertaken...
  55. ncbi request reprint Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women
    B J Orr Walker
    Department of Medicine, University of Auckland, New Zealand
    J Clin Endocrinol Metab 84:1997-2001. 1999
    ..These may contribute to the effects of HRT and menopause on many tissues and disease processes, including the development of osteoporosis...
  56. ncbi request reprint Determinants of vitamin D status in older women living in a subtropical climate
    Jenny A Lucas
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    Osteoporos Int 16:1641-8. 2005
    ..Our findings support the suggestion that vitamin D supplementation should become standard practice in this population of women, particularly during winter...
  57. doi request reprint High-dose oral vitamin D3 supplementation in the elderly
    C J Bacon
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 20:1407-15. 2009
    ..With baseline 25OHD > 50 nmol/L, vitamin D supplementation does not reduce PTH levels...
  58. ncbi request reprint The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women
    M J Bolland
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 18:479-86. 2007
    ..The improvements in bone density seen in the first 2 years were sustained throughout the extension study. Thiazides provide a further option in the prevention of postmenopausal bone loss...
  59. ncbi request reprint Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review
    Nancy K Latham
    Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
    J Am Geriatr Soc 51:1219-26. 2003
    ..identify, appraise, and synthesize data from randomized, controlled trials of vitamin D supplementation in older people...
  60. ncbi request reprint Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy
    Fiona Wu
    Department of Medicine, University of Auckland, New Zealand
    Clin Endocrinol (Oxf) 56:703-11. 2002
    ..To prospectively assess bone density and the factors determining the rate of bone loss over a 10-year period of postmenopausal life...
  61. doi request reprint The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
    S Bourke
    Department of Rheumatology, Auckland City Hospital, Auckland, New Zealand
    Osteoporos Int 24:349-54. 2013
    ....
  62. ncbi request reprint Determinants of vitamin D status in older men living in a subtropical climate
    M J Bolland
    Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    Osteoporos Int 17:1742-8. 2006
    ....
  63. ncbi request reprint Lactoferrin and bone; structure-activity relationships
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019 Auckland, New Zealand
    Biochem Cell Biol 84:297-302. 2006
    ..We conclude that lactoferrin might have a physiological role in bone growth and healing and a potential therapeutic role as an anabolic factor in osteoporosis...
  64. ncbi request reprint Leukemia inhibitory factor is mitogenic to osteoblasts
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    Bone 21:243-7. 1997
    ..They were not found in the acid phosphatase-positive staining osteoclasts. These results indicate that cells which have a mitogenic response to LIF are bone-forming rather than bone-resorbing cells...
  65. ncbi request reprint Alteration of bone cell function by RANKL and OPG in different in vitro models
    J M Lin
    University of Auckland, Auckland, New Zealand
    Eur J Clin Invest 37:407-15. 2007
    ..However, their effects in mature bone cells and in organ cultures have not been well studied. It is uncertain whether their activities in different experimental models are comparable...
  66. ncbi request reprint Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice
    J Cornish
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Endocrinol 170:251-7. 2001
    ..It is concluded that adrenomedullin(27-52) acts as an anabolic agent on bone. These findings may be relevant to the normal regulation of bone mass and to the design of agents for the treatment of osteoporosis...
  67. doi request reprint Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis
    Shyam Sankaran
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    J Clin Endocrinol Metab 95:1653-62. 2010
    ..Uncertainty exists as to the optimal management and monitoring of the skeletal consequences of mild primary hyperparathyroidism (PHPT)...
  68. ncbi request reprint A potential role for adrenomedullin as a local regulator of bone growth
    D Naot
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 142:1849-57. 2001
    ....
  69. ncbi request reprint Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    J Endocrinol 175:405-15. 2002
    ..When administered systemically, the direct actions of leptin outweigh its centrally mediated effects on bone, the latter possibly being mediated by leptin's regulation of insulin sensitivity...
  70. ncbi request reprint Adrenomedullin--a regulator of bone formation
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Regul Pept 112:79-86. 2003
    ..Thus, these small peptides, or their analogues, are attractive candidates as anabolic therapies for osteoporosis...
  71. ncbi request reprint Calcium supplementation does not affect CRP levels in postmenopausal women--a randomized controlled trial
    A Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Osteoporos Int 17:1141-5. 2006
    ..Epidemiological studies suggest that calcium supplementation may decrease the risk of cardiovascular disease...
  72. doi request reprint Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women
    C J Bacon
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 21:1935-41. 2010
    ....
  73. ncbi request reprint Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 144:1194-201. 2003
    ..Combined, these studies indicate that IL-18 may have an autocrine/paracrine mitogen role for both osteogenic and chondrogenic cells, independent of the production of IFNgamma or GM-CSF...
  74. ncbi request reprint Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
    J Cornish
    Department of Medicine and School of Biological Sciences, University of Auckland, Auckland, New Zealand
    Bone 29:162-8. 2001
    ..This activity is shared by amylin and CGRP. The much greater potency of calcitonin than amylin and CGRP is consistent with the action of these peptides being mediated by calcitonin receptors...
  75. doi request reprint Actions of fibroblast growth factor-8 in bone cells in vitro
    Jian Ming Lin
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Am J Physiol Endocrinol Metab 297:E142-50. 2009
    ..These data suggest that FGF-8 may have a physiological role in bone acting in an autocrine/paracrine manner...
  76. ncbi request reprint Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures
    Fiona Wu
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Arch Intern Med 162:33-6. 2002
    ..Perimenopausal and postmenopausal fractures are well-recognized, strong, independent predictors of subsequent fractures. However, it is unknown whether premenopausal fractures are predictive of postmenopausal fractures...
  77. ncbi request reprint Increased abdominal fat in young women of Indian origin
    Brandon Orr-Walker
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
    Asia Pac J Clin Nutr 14:69-73. 2005
    ..001), with marked differences evident even in the youngest group (mean age 23 years). Compared to other racial groups, women of Indian origin preferentially accumulate abdominal fat--a trait that is well established in young adulthood...
  78. ncbi request reprint Spinal bone density in women using depot medroxyprogesterone contraception
    T Cundy
    Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Obstet Gynecol 92:569-73. 1998
    ..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
  79. ncbi request reprint Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate
    A Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 74:542-50. 2004
    ....
  80. ncbi request reprint Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    Endocrinology 138:1299-304. 1997
    ....
  81. doi request reprint In vitro and in vivo effects of adiponectin on bone
    Garry A Williams
    Department of Medicine, University of Auckland, Auckland 1142, New Zealand
    Endocrinology 150:3603-10. 2009
    ..Because adiponectin does influence bone mass in vivo, it is likely to be a contributor to the fat-bone relationship...
  82. pmc Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
    Mark J Bolland
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
    BMJ 341:c3691. 2010
    ..To investigate whether calcium supplements increase the risk of cardiovascular events...
  83. ncbi request reprint Bisphosphonates in pregnancy and lactation-associated osteoporosis
    S M O'Sullivan
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Osteoporos Int 17:1008-12. 2006
    ..The aetiology is uncertain, and its management and natural history poorly defined...
  84. ncbi request reprint Bone mineral density in patients with treated Addison's disease
    G D Braatvedt
    Department of Medicine, University of Auckland, Private Bag, Auckland, New Zealand
    Osteoporos Int 10:435-40. 1999
    ..Unexpected hypogonadism in men with Addison's disease is common...
  85. ncbi request reprint The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes
    G D Braatvedt
    University Department of Medicine, Auckland Hospital, University of Auckland, Auckland, New Zealand
    Bone 35:766-70. 2004
    ..We conclude that atorvastatin (40 mg/day) has no significant effect on bone turnover in man...
  86. ncbi request reprint A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, University of Auckland, 1001 Auckland, New Zealand
    J Clin Endocrinol Metab 88:78-81. 2003
    ..0%, P = 0.029). There were no major adverse events. These data support the view that the likely cause of DMPA-associated bone loss is estrogen deficiency and demonstrate that it can be arrested by estrogen replacement therapy...
  87. doi request reprint Effect of osteoporosis treatment on mortality: a meta-analysis
    Mark J Bolland
    Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    J Clin Endocrinol Metab 95:1174-81. 2010
    ..Conclusions: Treatments for osteoporosis with established vertebral and nonvertebral fracture efficacy reduce mortality in older, frailer individuals with osteoporosis who are at high risk of fracture...
  88. ncbi request reprint The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Endocrinology 143:4755-63. 2002
    ..These data demonstrate that LPA and S1P potently promote osteoblast survival in vitro, and that cell-type specificity exists in the antiapoptotic signaling pathways activated by phospholipids...
  89. ncbi request reprint Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone
    Dorit Naot
    Department of Medicine, University of Auckland, New Zealand
    J Bone Miner Res 22:298-309. 2007
    ..We identified several differentially regulated genes, and we suggest that these changes could lead to the formation of the lesions...
  90. ncbi request reprint Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, The University of Auckland, and the Family Planning Association of New Zealand
    Am J Obstet Gynecol 186:978-83. 2002
    ..The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot medroxyprogesterone acetate contraception through to menopause...
  91. ncbi request reprint Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women
    Mark J Bolland
    Osteoporosis Research Group, Department of Medicine, University of Auckland Private Bag 92 019, Auckland 1020, New Zealand
    Bone 38:317-21. 2006
    ..This association between fat mass and PTH might contribute to the association between primary hyperparathyroidism and increased body weight...
  92. ncbi request reprint Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 90:2122-6. 2005
    ..Some patients with PHPT may experience an increase in urinary calcium excretion after vitamin D repletion...
  93. doi request reprint Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 25:2251-5. 2010
    ..These data demonstrate that the antiresorptive effects of a single 5-mg dose of zoledronate are sustained for 3 years; clinical trials to investigate the antifracture efficacy of dosing intervals longer than 1 year are justified...
  94. ncbi request reprint Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy
    Mark J Bolland
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 65:191-7. 2006
    ..We sought to determine whether BMD in HIV-infected men treated with HAART for at least 3 months is different from that in healthy controls, and, if so, what HIV-related factors might explain this finding...
  95. ncbi request reprint Calcium sensing receptor gene A986S polymorphism and responsiveness to calcium supplementation in postmenopausal women
    Robert Young
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Clin Endocrinol Metab 88:697-700. 2003
    ..These results are in contrast to those in young or premenopausal women, and they provide no support for an important role for the CASR A986S polymorphism in osteoporosis...
  96. doi request reprint Evaluation of the FRAX and Garvan fracture risk calculators in older women
    Mark J Bolland
    Department of Medicine, University of Auckland, Auckland 1142, New Zealand
    J Bone Miner Res 26:420-7. 2011
    ..The calibration varied, suggesting that the calculators should be validated in local cohorts before clinical use...
  97. ncbi request reprint Association of fat-free mass and training status with left ventricular size and mass in endurance-trained athletes
    Gillian A Whalley
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Am Coll Cardiol 44:892-6. 2004
    ..We sought to study the relationship between left ventricular (LV) size and body composition in male endurance athletes and age-matched control subjects...
  98. ncbi request reprint The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Mol Endocrinol 18:2268-78. 2004
    ....
  99. ncbi request reprint The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency
    Mark J Bolland
    Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    N Z Med J 121:63-74. 2008
    ..To explore the effects of seasonal variation on the diagnosis of vitamin D sufficiency and to determine whether age, gender, and ethnicity modify these effects...
  100. ncbi request reprint Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Biophys Res Commun 318:240-6. 2004
    ..Our findings are potentially important in refining these peptides for the therapy of osteoporosis...